CD19 and COVID-19: Hence, in this paper we performed a retrospective multicenter study and analyzed the details of R/R B‐cell lymphoma patients who received CD19 targeted CAR‐T heretofore in five cellular immunotherapy centers in China during the omicron wave, trying to provide suggestions on CAR‐T whole‐course management for COVID‐19.